Recently, the SK2 selective inhibitor, ABC294640 was demonstrated to induce proteasomal degradation of c-Myc and myeloid cell leukemia 1 (Mcl-1) in multiple myeloma cells [14]. Here, MCL1 is linked to plasma cell myeloma.